
THE SHROOMVERSE JOURNAL ✳ 17 MIN READ
How long do magic mushrooms last? Onset, peak and after-effects
Topic: Safety and risk
Published Updated
Short answer, checked 4 October 2026
How long do magic mushrooms last? Health Canada says effects appear within 15 to 45 minutes and usually last four to six hours. In studies of oral psilocybin, blood levels of psilocin, the active form, peaked about two hours after the dose on average and halved every two to three hours. Those are group averages. Mushroom strength, the person, the setting and the experience itself all shift the timing, so no timeline shows when it is safe to drive or take on responsibilities. After-effects described in the literature range from headache and nausea to, rarely, lasting distress or perceptual changes.
On this page 8 sections
Health Canada says the effects of magic mushrooms appear within 15 to 45 minutes and usually last four to six hours (Health Canada, page last modified 20 October 2026). That is the short answer to how long magic mushrooms last. It is a typical range from an official summary, not a promise for any one person or any one mushroom. This guide sets out where the figure comes from, what pharmacokinetic studies and clinical trials add, why real timing varies, and what the literature says about after-effects.
A timeline is not a safety tool
Everything here describes published research and official statements. It is not advice, it contains no dosing information, and no figure on this page marks a window in which anything is safe. Timing in studies comes from groups of screened volunteers who were given measured amounts of psilocybin, usually under supervision. Mushrooms bought or found outside a study are a different situation. Our safety page keeps emergency numbers.
How long do magic mushrooms last?
Four sources give timing figures for oral psilocybin. They measure different things, so they are not interchangeable. Health Canada describes effects people notice. The three studies measure blood levels of psilocin, the form the body makes from psilocybin and the one that shows up in blood. In Brown and colleagues' study of 12 adults, no psilocybin itself was found in plasma or urine (Brown et al., 2017).
| Source | What it reports | What to keep in mind |
|---|---|---|
| Health Canada (official page) | Effects appear within 15 to 45 minutes and usually last four to six hours. | A general summary for magic mushrooms. The page does not say how the range was derived. |
| Hasler et al., 1997 (six volunteers) | Peak plasma psilocin about 105 minutes after the dose, give or take 37 minutes. | Six people. It measures blood levels, not what was felt. |
| Brown et al., 2017 (12 adults) | Psilocin elimination half-life of 3 hours (standard deviation 1.1). Blood and urine were sampled over 24 hours. | The half-life is the time for the blood level to halve. Some people had a longer tail. |
| Hampsey et al., 2026 (systematic review, 12 oral trial arms) | Peak at 1.3 to 3.7 hours (mean 2.1). Half-life 1.8 to 3 hours (mean 2.6). | Pooled across trial arms of measured oral psilocybin, not mushrooms and not individuals. |
Evidence: established as a general pattern, with wide spread. Sources: Health Canada; Hasler et al., 1997; Brown et al., 2017; Hampsey et al., 2026.
How long until magic mushrooms kick in?
Health Canada gives 15 to 45 minutes for effects to appear (Health Canada). In the 1997 study, psilocin reached its highest blood level much later, at about 105 minutes on average, and the individual spread was wide (Hasler et al., 1997). The two figures measure different things, felt effects and blood level, so they need not coincide. The same study found that after an intravenous dose, psilocin appeared within minutes, which the authors read as rapid conversion of psilocybin in the body (Hasler et al., 1997).
How long does the peak last?
We could not find a source we could open that states how long the peak itself lasts, so we do not give one. What the literature does show is when intensity tends to be highest. Hampsey and colleagues' discussion puts maximal intensity of psilocin's effects at about 2.1 hours, citing another study, (Hampsey et al., 2026).
In a 2004 dose-effect study of eight volunteers, scores for altered states of consciousness rose with the dose, and the hormones the team measured (TSH, ACTH and cortisol) were elevated during peak effects at the highest dose tested (Hasler et al., 2004). Abstract consulted; we could not open the full text for its time points.
Why do trial sessions run much longer than four to six hours?
In the Hampsey review, session duration is the time from the dose to the last observation. For the oral psilocybin arms it ranged from 6 to 24 hours (mean 15.3) (Hampsey et al., 2026). Brown and colleagues monitored participants for 24 hours (Brown et al., 2017). Those figures describe how studies are run and watched, not how long effects last. They do show that researchers do not treat the end of the four-to-six-hour window as the end of observation.

Do magic mushrooms last longer than LSD?
Not by blood-level measures. In the same review, oral LSD arms had a peak at 0.5 to 2.0 hours (mean 1.43) and a half-life of 2.5 to 8.25 hours (mean 3.98), against 1.8 to 3 hours for psilocin. The authors describe psilocybin's elimination as more rapid than LSD's (Hampsey et al., 2026). Both are blood-level measures from trials. For how the two drugs differ more broadly, see our guide to psilocybin, LSD and DMT. DMT’s much shorter time course is covered in how long DMT lasts.
Why do magic mushrooms last longer for some people and some mushrooms?
Published sources point to several reasons. None of them can be seen or checked from the outside.
- The mushroom. Health Canada says strength can vary greatly and that one mushroom may hold different concentrations of the active ingredients than another (Health Canada). In a 2026 study, 14 Psilocybe cubensis strains grown under uniform lab conditions differed by more than 7.8-fold in total tryptamines, and psilocybin varied by 12.8% to 23.4% (coefficient of variation) between single mushrooms within strains (Sharchaton et al., 2026). Our explainer on blue bruising covers more of this.
- The body. Peak blood levels of psilocin ranged from 8.2 to 37.6 ng/mL across trial arms, which the reviewers called considerable variation (Hampsey et al., 2026). Brown and colleagues found an extended elimination phase in some people, and clearance was not predicted by body weight (Brown et al., 2017). Whether genetic differences in metabolism explain some of this for psilocybin is uncertain; the evidence so far is mostly preclinical (Hampsey et al., 2026).
- The person and the setting. CAMH says how hallucinogens feel depends on mood, expectation, environment, age, existing conditions and other substances (CAMH). In a pooled analysis of 23 studies (409 administrations), dose was the strongest predictor, but personality, mood before the dose and the experimental setting also contributed significantly (Studerus et al., 2012).
- Other substances. Health Canada says combining magic mushrooms with substances such as cannabis, amphetamines or alcohol raises the risk of serious side effects and adverse events (Health Canada).
- The experience itself. CAMH says effects vary from person to person, from one occasion to the next, and can change dramatically within a single occasion (CAMH). Health Canada lists an altered sense of time among the effects (Health Canada), so a person's own sense of how long it has been is not a reliable clock either.
The CAMH page is a general hallucinogens page whose copyright line reads 2004, 2009, so we use it only for general statements about hallucinogens, not for psilocybin-specific figures.
Why is a general timeline not a safety tool?
A range such as four to six hours describes the middle of a distribution. The tails matter more for safety, and the sources show they are long. Even among a handful of volunteers given measured amounts, the time of the peak blood level in the 1997 study had a standard deviation of 37 minutes around an average of about 105 (Hasler et al., 1997), and across trial arms the peak ranged from 1.3 to 3.7 hours (Hampsey et al., 2026).
Difficult experiences can also outlast a short window. In an anonymous online survey of 1,993 people describing their single most challenging experience with psilocybin mushrooms, the difficult portion lasted an hour or less for 31%, one to two hours for 25% and two hours or longer for 40% (Carbonaro et al., 2016). The authors note limits: they cannot know whether respondents were truthful, and many people did not finish the survey. Durations are the respondents' own estimates. Evidence: preliminary. It cannot tell us how common hard experiences are, only what people who chose to report one described.

Health Canada says a "bad trip" may occur, particularly at high doses, and may include paranoia, loss of boundaries and a distorted sense of self. It adds that impaired judgement during these experiences may lead to risk-taking behaviour, which may then lead to traumatic injuries or even death (Health Canada). Johnson and colleagues' safety guidelines for research name a "bad trip" (anxiety, fear or panic, dysphoria and paranoia) as the most likely risk of hallucinogens, one that could lead to dangerous behaviour (Johnson et al., 2008). A clock cannot tell anyone whether that is happening.
If someone is in distress, or may have eaten a wild mushroom
In an emergency call 911. The Ontario Poison Centre answers questions about poisoning by phone at 1-800-268-9017, toll-free, 24 hours a day. For wild mushrooms it says not to wait until the person feels sick, because illness can take many hours to appear (Ontario Poison Centre). Our safety page keeps these numbers, and our bad-trip article covers what official sources say.
Can you drive or take on commitments after magic mushrooms?
No official source we read gives a time after which driving after psilocybin is treated as acceptable. What the sources do say is below. This is general information, not legal advice; check the current wording on the official pages.
- The Criminal Code makes it an offence to operate a conveyance while the person's ability to operate it is "impaired to any degree" by alcohol or a drug (Criminal Code, section 320.14, current to 21 September 2026).
- A separate route does not depend on showing impairment. Under the Blood Drug Concentration Regulations, the level for psilocybin and for psilocin is "any detectable level" (Blood Drug Concentration Regulations, current to 21 September 2026). The Criminal Code's blood-concentration offence (section 320.14) looks at the blood concentration within two hours of driving, and Justice Canada's explainer lists psilocybin and psilocin (magic mushrooms) among the drugs set at any detectable level (Justice Canada FAQ, modified 7 July 2021).
- In research, Johnson and colleagues' guidelines say that participants released after a session should be instructed not to drive or do anything else potentially dangerous for the rest of the day. They also say participants should be released after the effects have resolved, into the care of a friend or family member or kept overnight (Johnson et al., 2008). That is a research-protocol statement, not a rule for anyone else.
- Health Canada's magic mushrooms page does not mention driving, so the legal and research statements above are what we can cite.
On commitments such as contracts, work or caring for others, we found no official page that addresses them directly. What exists are general statements about judgement. CAMH says hallucinogens affect perception and behaviour and may cause disorientation, poor judgement and risk-taking (CAMH), and Health Canada links impaired judgement to risk-taking (Health Canada). Detectability and impairment are also different questions, which is why the law has both routes above. How long psilocybin can be detected is the subject of a separate article. For the legal position more broadly, see are magic mushrooms legal in Canada.
What are the after-effects of magic mushrooms?
The literature separates what people report in the hours and days afterwards from rarer lasting effects. We label the strength of each.
In the hours and days after
The most useful figures come from trials. In a phase 2 trial of 233 people with treatment-resistant depression, adverse events occurred in 179 (77%), including headache, nausea and dizziness, and suicidal ideation or behaviour or self-injury occurred in all dose groups (Goodwin et al., 2022). The abstract gives the overall rate, not the timing of each event. Evidence: established for that trial population; it does not tell us the rate for anyone else.
In a pooled analysis of eight placebo-controlled studies of 110 healthy volunteers, strong dysphoria or anxiety and panic occurred only at the two highest dose conditions and in a relatively small proportion of people. Follow-up questionnaires found no later drug abuse, persisting perception disorder, prolonged psychosis or other long-term impairment in any of them. The authors stress that these participants were healthy, high-functioning and well prepared, in a carefully monitored setting (Studerus et al., 2011). Evidence: established for screened volunteers in supervised research; do not read it as a general guarantee.
Research teams also schedule follow-up after sessions, typically the next day, to check psychological stability and to give participants a chance to talk through the experience (Johnson et al., 2008). Health Canada adds that tolerance to the effects can develop over several days of continued use (Health Canada).

Flashbacks and persisting perception changes
Official sources mention flashbacks without giving a duration. Health Canada says frequent or overly intense psychedelic events may induce abrupt flashbacks, meaning reliving the experience (Health Canada). CAMH says flashbacks may occur on rare occasions, days, weeks or even years after use (CAMH).
The research literature draws a distinction. Johnson and colleagues describe "flashback" as often used for brief perceptual effects that return after the drug has worn off, usually without distress or impairment. Hallucinogen persisting perception disorder (HPPD) is a diagnosis in which such effects are clinically distressing or impair functioning. Its incidence is unknown, thought to be very uncommon, and appears much lower in careful research settings than in illicit use (Johnson et al., 2008). A 2003 review of 20 quantitative studies found current knowledge of HPPD very limited and the word "flashbacks" defined in so many ways that it is "essentially valueless". It describes HPPD as a genuine but uncommon disorder, sometimes lasting months or years, reported most often after illicit LSD and less often with other hallucinogens (Halpern and Pope, 2003). Evidence: unresolved for how often it follows psilocybin mushrooms specifically.
Lasting distress after a hard experience
CAMH says some people who take hallucinogens feel depressed or anxious long after they took the drug (CAMH). The Carbonaro survey gives the most detail for psilocybin mushrooms. Among 1,339 respondents whose challenging experience was at least a year earlier, 24% reported fear, anxiety, depression, paranoia or other symptoms lasting a week or longer that they attributed to it. About 10% reported symptoms lasting 12 months or more, and 7.6% sought professional treatment for them. Across all 1,993 respondents, three cases appeared linked to the onset of lasting psychotic symptoms and three to attempted suicide (Carbonaro et al., 2016).
These are self-reports from an anonymous survey of people who picked their worst experience, so they cannot give a rate for people in general. The authors themselves say the risk of risky behaviour and enduring distress is extremely low in laboratory studies of screened, prepared and supported participants (Carbonaro et al., 2016). Evidence: preliminary.
What we still don't know
- How long the peak lasts. We found no source we could open that states it (unresolved).
- How much whole mushrooms differ from the measured oral psilocybin used in trials. Trial timing may not transfer to mushrooms of unknown strength, and we found no comparison that settles it (unresolved).
- Whether preparation, food or other factors change timing for whole mushrooms. We did not find a source we could verify, so we say nothing about it (unresolved).
- How often lasting distress or perceptual changes follow psilocybin outside research. Surveys are self-selected, and the incidence of HPPD is unknown (unresolved).
- Long-term effects of repeated use. Health Canada says no studies have evaluated them (Health Canada) (unresolved).
The honest answer to how long magic mushrooms last is a range with long tails, and that is exactly why a number should not be used to decide anything about safety. Check the date on this page before relying on it. Next, read what magic mushrooms are, or what psilocybin is. The legal side is covered in our Canadian law explainer.
Common questions
How long do magic mushrooms last?
Health Canada says effects appear within 15 to 45 minutes and usually last four to six hours. In studies of oral psilocybin, blood levels of psilocin peaked at about 1.3 to 3.7 hours across trial arms, and the half-life was about 1.8 to 3 hours. These are group averages with wide individual spread.
How long until magic mushrooms kick in?
Health Canada gives 15 to 45 minutes for effects to appear. In a 1997 study of six volunteers, blood levels of psilocin peaked later, at about 105 minutes on average (standard deviation 37 minutes).
Why do magic mushrooms last longer for some people?
Published sources point to mushroom strength (which varies widely, even between mushrooms of the same strain), differences in how bodies process psilocin, mood and setting, other substances, and the changing nature of the experience itself. None of these can be judged from outside, which is why a general timeline cannot tell anyone how long it will last for them.
Can you drive after magic mushrooms?
The Criminal Code prohibits driving while impaired to any degree by a drug, and the Blood Drug Concentration Regulations set psilocybin and psilocin at "any detectable level". We found no official source that gives a waiting time after which driving is treated as acceptable. This is general information, not legal advice.
What are the after-effects of magic mushrooms?
In a large phase 2 trial, adverse events including headache, nausea and dizziness were reported by 77% of participants. Rarer lasting effects described in the literature include flashbacks, HPPD and, in a self-selected survey, distress lasting weeks or months. Rates for people outside research are not known.
Can magic mushrooms cause flashbacks, and how long do they last?
Health Canada and CAMH both say flashbacks can occur, and CAMH says they may come days, weeks or even years later. Researchers distinguish brief flashbacks, usually without distress or impairment, from HPPD, a rare diagnosis in which perceptual effects are distressing or impairing. How long they last varies, and the sources give no typical duration.
What if it feels like it is lasting too long, or someone is in distress?
In an emergency call 911. The Ontario Poison Centre answers poisoning questions 24 hours a day at 1-800-268-9017 and says not to wait for symptoms after someone eats wild mushrooms. See our safety page for numbers and our bad-trip article for what official sources say.
Shroomverse sells mushroom products. This article is general information about what published research and official sources say about timing. It is not medical, legal or purchasing advice, and it does not encourage anyone to use drugs.
SOURCES
- Psilocybin and psilocin (Magic mushrooms), Health Canada. Accessed . Supports: effects appear within 15 to 45 minutes and usually last four to six hours; strength varies; altered sense of time; bad trips, risk-taking and flashbacks; tolerance over several days; combining with other substances; no studies on long-term effects of repetitive use; production, sale and possession illegal. Page date modified 20 October 2026; re-read 24 October 2026. The page does not mention driving.
- Hallucinogens (CAMH information page), Centre for Addiction and Mental Health (CAMH). Accessed . Supports: factors that shape the feeling, variation within one occasion, poor judgement and risk-taking, flashbacks, long-lasting low mood or anxiety. A general hallucinogens page (copyright 2004, 2009) with no psilocybin-specific timing.
- Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man (Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX, Pharmaceutica Acta Helvetiae 72(3):175–184, 1997), Elsevier (peer-reviewed); abstract consulted via Europe PMC, DOI confirmed in Crossref. Accessed . Supports: peak plasma psilocin after oral psilocybin at 105 ± 37 minutes in six volunteers; rapid appearance of psilocin after intravenous dose. Abstract consulted; full text not open.
- Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study (Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX, Psychopharmacology 172(2):145–156, 2004), Springer (peer-reviewed); abstract consulted via Europe PMC, DOI confirmed in Crossref. Accessed . Supports: dose-dependent effects in eight volunteers and hormone elevations during peak effects. Abstract consulted; full text not open, so no time points are quoted from it.
- Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults (Brown RT, et al., Clinical Pharmacokinetics 56(12):1543–1554, 2017), Springer (peer-reviewed); abstract consulted via Europe PMC, DOI confirmed in Crossref. Accessed . Supports: 12 adults, 24-hour monitoring, no psilocybin found in plasma or urine, psilocin half-life of 3 hours (SD 1.1), extended elimination phase in some people, clearance not predicted by body weight. Abstract consulted; full text not open.
- A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects (Hampsey E, et al., Journal of Psychopharmacology 40(8):1213–1223, 2026), SAGE (peer-reviewed, open access); full text via PubMed Central, PMC13415903. Accessed . Supports: pooled ranges for oral psilocybin (peak 1.3 to 3.7 hours, half-life 1.8 to 3 hours, peak concentration 8.2 to 37.6 ng/mL, session duration 6 to 24 hours), the LSD comparison, interindividual variability and the uncertainty about pharmacogenetics.
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies (Studerus E, Kometer M, Hasler F, Vollenweider FX, Journal of Psychopharmacology 25(11):1434–1452, 2011), SAGE (peer-reviewed); abstract consulted via Europe PMC, DOI confirmed in Crossref. Accessed . Supports: 110 healthy volunteers across eight studies, adverse reactions limited to the highest doses, follow-up findings, and the authors' caveat about screened, prepared participants. Abstract consulted; full text not open.
- Prediction of Psilocybin Response in Healthy Volunteers (Studerus E, Gamma A, Kometer M, Vollenweider FX, PLoS ONE 7(2):e30800, 2012), PLOS (peer-reviewed, open access); full text via PubMed Central, PMC3281871. Accessed . Supports: pooled analysis of 23 studies and 409 administrations; dose the strongest predictor, with personality, mood and setting also contributing.
- Human hallucinogen research: guidelines for safety (Johnson M, Richards W, Griffiths R, Journal of Psychopharmacology 22(6):603–620, 2008), SAGE (peer-reviewed); full text via PubMed Central, PMC3056407. Accessed . Supports: a “bad trip” (anxiety, fear or panic, dysphoria, paranoia) as the most likely risk; the research instruction not to drive or do other dangerous activity for the rest of the day; next-day follow-up; the flashback and HPPD definitions and the statements on incidence.
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences (Carbonaro TM, et al., Journal of Psychopharmacology 30(12):1268–1278, 2016), SAGE (peer-reviewed); full text via PubMed Central, PMC5551678. Accessed . Supports: duration categories of the difficult portion, the enduring-symptom figures, the cases of psychosis and attempted suicide, and the survey's stated limitations.
- Hallucinogen persisting perception disorder: what do we know after 50 years? (Halpern JH, Pope HG, Drug and Alcohol Dependence 69(2):109–119, 2003), Elsevier (peer-reviewed review); abstract consulted via Europe PMC, DOI confirmed in Crossref. Accessed . Supports: 20 quantitative studies reviewed, the limits of current knowledge, the problem with the term "flashbacks", and the description of HPPD as genuine but uncommon. Abstract consulted; full text not open.
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (Goodwin GM, et al., New England Journal of Medicine 387(18):1637–1648, 2022), Massachusetts Medical Society (peer-reviewed); abstract consulted via Europe PMC, DOI confirmed in Crossref. Accessed . Cited only for the adverse-event figures (179 of 233, 77%; headache, nausea, dizziness; suicidal ideation or behaviour or self-injury in all dose groups). Abstract consulted; full text not open. Not cited for any efficacy claim.
- Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions (Sharchaton A, et al., Journal of Fungi 12(7):486, 2026), MDPI (peer-reviewed, open access); full text via PubMed Central, PMC13412672. Accessed . Supports: more than 7.8-fold variation in total tryptamines among 14 strains under uniform conditions, and psilocybin coefficients of variation of 12.81% to 23.39% between single fruiting bodies within strains.
- Criminal Code, section 320.14 (Operating a conveyance while impaired), Justice Laws Website, Government of Canada. Accessed . Supports: the offence of operating a conveyance while impaired to any degree by alcohol or a drug. Current to 21 September 2026. Check the live page for any later change.
- Blood Drug Concentration Regulations (SOR/2018-148), Justice Laws Website, Government of Canada. Accessed . Supports: psilocybin and psilocin listed at "any detectable level" in the hybrid-offence table. Current to 21 September 2026.
- Frequently Asked Questions - Drug-Impaired Driving Laws, Department of Justice Canada. Accessed . Supports: psilocybin and psilocin (magic mushrooms) are among the drugs set at any detectable level. The page's own two-hour wording names other drugs, so the two-hour point is taken from the Criminal Code. Page modified 7 July 2021; the regulations above are the newer source for the levels.
- Ontario Poison Centre: home page, Ontario Poison Centre, operated by The Hospital for Sick Children (SickKids), Toronto. Accessed . Source for the toll-free number 1-800-268-9017 and 24-hour availability.
- Mushrooms (public information page), Ontario Poison Centre. Accessed . Supports: for wild mushrooms, do not wait until the person feels sick to call; illness may not appear for many hours.
CHANGES
- : Added links to the DMT Library.
- : Published.
- : Re-read Health Canada’s psilocybin page, updated on 20 October 2026, and corrected its date here. The statements this article cites from it are unchanged.



